Cost-effectiveness Analysis of Pembrolizumab monotherapy and Chemotherapy in the Non-small-cell Lung Cancer with different PD-L1 Tumor Proportion Scores

Lung cancer is the leading cause of cancer-related deaths worldwide and can be broadly classified into two types: non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The former represents 85% of all lung cancer [1].

Source: Lung Cancer - August 25, 2019 Category: Cancer & Oncology Authors: Kexun Zhou, Chenlu Jiang, Qiu Li Source Type: research